Moderna, Inc.
MRNA Stock News
Latest MRNA news
Moderna CEO's Surprising Comment Gives Clues About Where Drugmaker Is Going Next
Barrons · Wed, 23 Sep 2026 12:53:00 -0400
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been' just a Covid vaccine company.
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Seeking Alpha · Wed, 23 Sep 2026 12:39:29 -0400
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID
MarketBeat · Wed, 23 Sep 2026 11:03:23 -0400
Moderna NASDAQ: MRNA executives emphasized the company's evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development.
Is Moderna Stock a Buy After Its Melanoma Breakthrough?
The Motley Fool · Tue, 22 Sep 2026 15:15:00 -0400
Moderna (MRNA +5.87%) may finally have the catalyst investors have been waiting for beyond COVID. A successful Phase 3 melanoma study strengthens the case for personalized mRNA cancer treatment, but the stock's huge rerating now leaves one question dominant: Can this become a durable oncology franchise, or has the market moved faster than the evidence?
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
24/7 Wall Street · Tue, 22 Sep 2026 10:51:51 -0400
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at scale. Moderna stock is at $181.
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No.
The Motley Fool · Tue, 22 Sep 2026 10:33:00 -0400
Moderna surged 177% after promising results from one of its cancer-related mRNA clinical trials. Analysts remain largely on the fence, with two analysts downgrading the stock to the equivalent of "sell" in recent weeks.
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
Zacks Investment Research · Tue, 22 Sep 2026 10:01:28 -0400
Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.
Market information is provided for research and visualization and is not investment advice.